Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.40 |
| ▸ | DRD3 | P35462 | 9/20 | 0.40 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31490161 | 1.00 | DRD2 (0.40) | DRD2DRD3LTA4HHTR1ASIGMAR1 | |
| SCHEMBL31490139 | 0.81 | KMT2A (0.41) | RAB9AACHE | |
| SCHEMBL23769124 | 0.81 | KMT2A (0.41) | RAB9AACHE | |
| SCHEMBL23769085 | 0.77 | MEN1 (0.39) | DRD2DRD3LTA4HSIGMAR1LMNA | |
| SCHEMBL31490283 | 0.77 | MEN1 (0.39) | DRD2DRD3LTA4HSIGMAR1LMNA | |
| SCHEMBL23769078 | 0.76 | DRD2 (0.34) | DRD2DRD3HTR1ASIGMAR1CYP2D6 | |
| SCHEMBL31490134 | 0.76 | DRD2 (0.34) | DRD2DRD3HTR1ASIGMAR1CYP2D6 | |
| SCHEMBL11145662 | 0.76 | EHMT2 (0.42) | DRD2DRD3LTA4HSIGMAR1 | |
| SCHEMBL23769067 | 0.74 | HDAC1 (0.34) | DRD2DRD3LMNA | |
| SCHEMBL31490092 | 0.74 | HDAC1 (0.34) | DRD2DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| CN-115151304-A | Small molecule interferon gene stimulating factor (STING) antagonists | 库拉德夫制药私人有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021161230-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | DRD2 3640/4885DRD3 4287/4885LTA4H 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.